Bloomberg Markets & Finance via Youtube


Sep.04 — The Food and Drug Administration could base its decision on approving a coronavirus vaccine on interim test results, according to Rasmus Bech Hansen, chief executive officer of Airfinity Ltd, an analytics company that tracks drug trials. The first readouts showing whether a vaccine can stop people from getting Covid-19 may come by mid-September from AstraZeneca Plc. Two other contenders — the U.S.’s Moderna Inc. and the U.S.-German partnership of Pfizer Inc. and BioNTech SE — may also have initial data before a key FDA meeting on scheduled for Oct. 22, Airfinity says.

READ ALSO  SE: Musk: Tesla Plans New $25,000 EV in About Three Years